In vitro effects of mitomycin-C on human keratocytes

J Refract Surg. 1998 Sep-Oct;14(5):534-40. doi: 10.3928/1081-597X-19980901-11.

Abstract

Background: The purpose of the present study is to quantify the in vitro antiproliferative and cytotoxic effects of mitomycin-C on human keratocytes for their potential to modulate corneal stromal wound healing.

Methods: Cultured human keratocytes were exposed to various concentrations of mitomycin-C for periods of 5 minutes and 1 hour. Keratocyte proliferation and viability were assessed by phase-contrast microscopy, 3H-thymidine uptake, and electronic cell counting.

Results: Cytotoxic changes and inhibition of keratocyte proliferation exhibited after exposure to mitomycin-C were both dose- and time-dependent. The lowest concentrations to significantly (> 50%) inhibit keratocyte proliferation after 5-minute exposures were 0.05 mg/ml (P < .005) and after 1-hour exposures were 0.005 mg/ml (P < .001). At 5 minutes, ID50 was 0.038 mg/ml and LD50 was much higher than the greatest concentration tested (0.5 mg/ml). Mitomycin-C's median inhibitory dose (ID50) and median lethal dose (LD50) after 1 hour of exposure differed by a magnitude of 50 (0.0048 vs. 0.28 mg/ml).

Conclusions: Mitomycin-C has antiproliferative effects at concentrations below those cytotoxic to human keratocytes. If used after photorefractive keratectomy, the drug should be administered at antiproliferative rather than cytotoxic concentrations.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibiotics, Antineoplastic / pharmacology*
  • Cell Count
  • Cell Division / drug effects
  • Cell Survival / drug effects
  • Cells, Cultured
  • Corneal Stroma / cytology
  • Corneal Stroma / drug effects*
  • DNA Replication / drug effects
  • Dose-Response Relationship, Drug
  • Fibroblasts / drug effects
  • Humans
  • Microscopy, Phase-Contrast
  • Mitomycin / pharmacology*
  • Time Factors

Substances

  • Antibiotics, Antineoplastic
  • Mitomycin